Mechanism of action

GHRP-6 stimulates release of endogenous GH rather than supplying the GH protein itself. Howard et al. (1996) characterized the receptor through which synthetic secretagogues act, distinguishing this pathway from the GHRH receptor. Bowers and colleagues observed increased circulating GH after exposure to the studied hexapeptide, with a larger response when it was combined with GHRH. Their endocrine measurements also included prolactin and cortisol changes under particular conditions. A combined response supports an interaction within the system; it does not establish that the peptides are identical, that all secretagogues have the same selectivity or that the hormone response produces a functional benefit.

State of evidence

Bowers et al. (1990) examined 18 healthy men using placebo and GHRH comparisons for acute responses. Jaffe et al. (1993) compared a prolonged GHRP-6 infusion with saline in nine healthy young men. They reported changes in GH pulse amplitude and integrated GH concentrations, together with increased IGF-I, while pulse frequency did not change in that experiment. These are controlled observations of hormone dynamics, not demonstrations of sustained improvements in strength or recovery. Cabrales' later study measured the peptide itself in human pharmacokinetic work, a different question from downstream GH responses. Findings should remain attached to the molecule, population and conditions examined. Neither receptor identification nor an endocrine response validates the effectiveness or safety of a separate research preparation.

Questions about the research

How do GHRP-6, GHRH and GH differ?

GHRP-6 is a short secretagogue, GHRH is a releasing hormone and GH is the larger protein whose secretion can be measured. They have different structures and receptor contexts. A larger combined hormone response does not make the molecules interchangeable.

Does higher GH or IGF-I establish greater muscle strength?

No. These are endocrine endpoints. A functional conclusion requires appropriate studies of that function in the population concerned. The selected human experiments primarily investigated hormone dynamics and cannot establish a general strength or recovery benefit.

Can modified GHRP-6 or GHRP-2 studies be counted as GHRP-6 evidence?

They require separate treatment. D-Lys3-GHRP-6 is a modified antagonist, and GHRP-2 is a different secretagogue. A similar family name does not identify the actual substance in an experiment. Findings must not be reassigned to ordinary GHRP-6 solely through that naming similarity.

Sources

1. Bowers et al., J Clin Endocrinol Metab 1990DOI: 10.1210/jcem-70-4-975PMID: 2108187
2. Jaffe et al., J Clin Endocrinol Metab 1993DOI: 10.1210/jcem.77.6.7903313PMID: 7903313
3. Howard et al., Science 1996, secretagogue-receptor identificationDOI: 10.1126/science.273.5277.974PMID: 8688086
4. Cabrales et al., Eur J Pharm Sci 2013, human intravenous peptide PKDOI: 10.1016/j.ejps.2012.10.006PMID: 23099431

Mechanism of action

GHRP-6 stimulates release of endogenous GH rather than supplying the GH protein itself. Howard et al. (1996) characterized the receptor through which synthetic secretagogues act, distinguishing this pathway from the GHRH receptor. Bowers and colleagues observed increased circulating GH after exposure to the studied hexapeptide, with a larger response when it was combined with GHRH. Their endocrine measurements also included prolactin and cortisol changes under particular conditions. A combined response supports an interaction within the system; it does not establish that the peptides are identical, that all secretagogues have the same selectivity or that the hormone response produces a functional benefit.

State of evidence

Bowers et al. (1990) examined 18 healthy men using placebo and GHRH comparisons for acute responses. Jaffe et al. (1993) compared a prolonged GHRP-6 infusion with saline in nine healthy young men. They reported changes in GH pulse amplitude and integrated GH concentrations, together with increased IGF-I, while pulse frequency did not change in that experiment. These are controlled observations of hormone dynamics, not demonstrations of sustained improvements in strength or recovery. Cabrales' later study measured the peptide itself in human pharmacokinetic work, a different question from downstream GH responses. Findings should remain attached to the molecule, population and conditions examined. Neither receptor identification nor an endocrine response validates the effectiveness or safety of a separate research preparation.

Questions about the research

How do GHRP-6, GHRH and GH differ?

GHRP-6 is a short secretagogue, GHRH is a releasing hormone and GH is the larger protein whose secretion can be measured. They have different structures and receptor contexts. A larger combined hormone response does not make the molecules interchangeable.

Does higher GH or IGF-I establish greater muscle strength?

No. These are endocrine endpoints. A functional conclusion requires appropriate studies of that function in the population concerned. The selected human experiments primarily investigated hormone dynamics and cannot establish a general strength or recovery benefit.

Can modified GHRP-6 or GHRP-2 studies be counted as GHRP-6 evidence?

They require separate treatment. D-Lys3-GHRP-6 is a modified antagonist, and GHRP-2 is a different secretagogue. A similar family name does not identify the actual substance in an experiment. Findings must not be reassigned to ordinary GHRP-6 solely through that naming similarity.

Sources

1. Bowers et al., J Clin Endocrinol Metab 1990DOI: 10.1210/jcem-70-4-975PMID: 2108187
2. Jaffe et al., J Clin Endocrinol Metab 1993DOI: 10.1210/jcem.77.6.7903313PMID: 7903313
3. Howard et al., Science 1996, secretagogue-receptor identificationDOI: 10.1126/science.273.5277.974PMID: 8688086
4. Cabrales et al., Eur J Pharm Sci 2013, human intravenous peptide PKDOI: 10.1016/j.ejps.2012.10.006PMID: 23099431